Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GALECTIN THERAPEUTICS INC Director's Dealing 2013

Nov 5, 2013

33422_dirs_2013-11-05_c786b082-8b04-4203-9037-2ae7540464f3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2013-11-01

Reporting Person: 10X Fund, L.P. (10% Owner)
Reporting Person: 10X Capital Management, LLC (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-11-01 Common Stock M 150000 $3.00 Acquired 9407422 Direct
2013-11-01 Common Stock M 50000 $3.00 Acquired 9457422 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-11-01 Class A-2 Warrants (right to buy) $3.00 M 150000 Disposed 2019-05-13 Common Stock (150000) Direct
2013-11-01 Class A-2 Warrants (right to buy) $3.00 M 50000 Disposed 2019-06-30 Common Stock (50000) Direct

Footnotes

F1: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

F2: On May 13, 2009, 10X Fund, L.P. purchased (a) 450,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 150,000 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 150,000 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 600,000 shares of Common Stock for $3.00 per share, for aggregate consideration of $900,000.

F3: On June 30, 2009, 10X Fund, L.P. purchased (a) 250,000 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 833,333 shares of Common Stock for $3.00 per share, (c) one Class A-2 Warrant to purchase 83,333 shares of Common Stock for $3.00 per share, and (d) one Class B Warrant to purchase 333,333 shares of Common Stock for $3.00 per share, for aggregate consideration of $500,000.